Automation software company UiPath (NYSE:PATH) reported in Q4 CY2025, with sales up 13.6% year on year to $481.1 million. Guidance for next quarter’s revenue was better than expected at $397.5 million ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. UiPath (NYSE:PATH) and Deloitte have expanded their ...

Turning to its guidance, UiPath sees revenue of $395 million to $400 million for its fiscal Q1 2027. For the full fiscal year 2027, the company sees revenue of $1.754 billion to $1.759 billion, ...

UiPath (NYSE:PATH) has launched agentic AI automation tools tailored for healthcare providers and payers. The company is partnering with Genzeon to target data management and revenue cycle workflows.

Detailed price information for Uipath Inc Cl A (PATH-N) from The Globe and Mail including charting and trades.

Software developer UiPath will cut 10% of its workforce, or about 420 jobs, as part of a broader company restructuring. UiPath shares fell 7% on Tuesday and have plunged more than 50% year-to-date. In ...

The company's expenses and the sudden resignation of its CEO are concerning. Yet, UiPath appears to have more going for it than its stock price may indicate. However, the robotics stock may have hit ...

UiPath’s blended fair value estimate has been trimmed from US$16.19 to US$15.93, a move that sits alongside bullish analyst price targets up to US$18 and recent target cuts from more cautious voices.

AI company UiPath was on a trajectory of double-digit, year-over-year revenue growth that suddenly stopped after Q1. The company lowered its fiscal 2025 revenue guidance, and its CEO resigned. Despite ...

UiPath Inc. today announced a preview of its upcoming Agent Builder tool as it outlined its vision to combine its expertise in robotic process automation with generative artificial intelligence models ...

UiPath closes fiscal year 2026 on a high, with co-Founder and CEO Daniel Dines making a bold case that falling AI development costs are good for the automation market, not a threat to it.

Morgan Stanley and shares of alternative asset managers slide amid renewed private-credit fears.